Form 4: Celldex Therapeutics Executive Acquires Stock Options

Elizabeth Crowley, SR. VP & CPDO of Celldex Therapeutics, acquired 85,000 incentive stock options on June 13, 2024, according to a Form 4 filing.

Summary

• Elizabeth Crowley, a Senior Vice President and CPDO at Celldex Therapeutics, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 13, 2024, where Crowley acquired 85,000 incentive stock options.
• These options, granted under the company's 2021 Omnibus Equity Incentive Plan, have an exercise price of $36.43.
• The options vest 25% on June 13, 2025, with the remaining portion vesting quarterly over the following 12 quarters.
• The options expire on June 13, 2034.
• Following the reported transaction, Crowley directly owns 85,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating an executive's acquisition of stock options, which can be interpreted as a sign of confidence, but it doesn't inherently indicate overwhelmingly positive or negative sentiment.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• The acquisition of stock options by a company executive can potentially align the interests of management with those of shareholders.

Key Dates